小金片治疗乳腺增生症的临床疗效

 目的 观察小金片治疗乳腺增生症的临床疗效,从而为小金片的临床应用提供证据。方法 选择武警总医院2016-02至2017-03乳腺增生症患者97例,按治疗情况分为小金片治疗组60例,其他药物(逍遥丸、乳癖消片、祛瘀散结胶囊)对照组37例,统计分析两组患者治疗前后乳腺结节的大小及疼痛改善情况,进一步评估两组患者临床疗效情况。结果 治疗前,两组患者乳腺结节最大直径[治疗组:(4.21±1.15)cm;对照组:(4.24±1.07)cm]以及疼痛评分[治疗组:(6.91±1.78)cm;对照组:(7.56±1.93)cm],未见明显差异。治疗后两组结节最大直径[治疗组:(0.93±0.35)cm;对照组:(2.23±0.58)cm],以及疼痛评分[治疗组:(2.07±0.68)cm;对照组:(3.88±1.41)cm]较治疗前明显改善(P<0.05)。相比于其他药物对照组,小金片治疗组患者乳腺结节最大直径(治疗前:4.21±1.15;治疗后:0.93±0.35)以及疼痛评分(治疗前:6.91±1.78;治疗后:2.07±0.68)都有明显下降,差异有统计学意义(P<0.05)。结论 小金片治疗乳腺增生症临床疗效显著。

Clinical effect of Xiaojin tablets on breast hyperplasia

Objective To investigate the therapeutic effect of Xiaojin tablets on breast hyperplasia, and provide evidence for their clinical application.Methods A total of 97 patients with breast hyperplasia admitted to our hospital between February 2016 and May 2017 were selected in this study. The patients were divided into Xiaojin tablet group (n=60) and the control group(n=37)treated with other drugs. The size of breast nodules and the improvement of pain from baseline were compared and analyzed to evaluate the clinical effect in these two groups.Results In the tablet group, the average maximum diameter of breast nodules before treatment was (4.21±1.15)cm, but was(0.93±0.35)cm after treatment. The average VAS prior to treatment was(6.91±1.78), compared with (2.07±0.68)after treatment. In the control group, the average maximum diameter of breast nodules was(4.24±1.07)cm prior to treatment, but was (2.23±0.58)cm after treatment. The average VAS before treatment was (7.56±1.93, but was(3.88±1.41)after treatment. After treatment, the maximum diameter of breast nodules and VAS in both groups were significantly improved. Compared to the control group, the maximum diameter of breast nodules and the pain score in Xiaojin tablet group were significantly decreased, and the difference was statistically significant(P<0.05). Conclusions Xiaojin tablets are quite effective for breast hyperplasia.